Status:
UNKNOWN
Gut Microbiota Metagenomics for Chronic Liver Disease
Lead Sponsor:
Chuncheon Sacred Heart Hospital
Conditions:
Liver Disease Chronic
Eligibility:
All Genders
31-82 years
Brief Summary
Gut microbiota modulation has effect on chronic liver disease
Detailed Description
Chronic liver disease has been known as a disease of the liver which lasts over a period of 6-month. It consists of inflammation, hepatitis, cirrhosis, hepatocellular carcinoma. Gut microbiota plays ...
Eligibility Criteria
Inclusion
- Age 19+
- Normal : AST or ALT level \< 50IU/L, BMI \< 25
- Liver disease : AST or ATL level ≥ 50IU/L, BMI ≥ 25
- Patients hospitalized with chronic liver disease (viral hepatitis, alcoholic liver disease, non-alcoholic liver disease, cirrhosis, liver cancer)
Exclusion
- Normal : AST or ATL level ≥ 50IU/L, BMI ≥ 25
- Liver disease : AST or ALT level \< 50IU/L, BMI \< 25
- If the patient refuses
Key Trial Info
Start Date :
April 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2025
Estimated Enrollment :
3240 Patients enrolled
Trial Details
Trial ID
NCT04339725
Start Date
April 1 2017
End Date
January 1 2025
Last Update
April 9 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Internal Medicine, Hallym University Chuncheon Sacred Heart Hospital
Chuncheon, South Korea, 200-704